Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact

Thrombosis Research

Volumn 125, Issue , 2010, Pages S55-S57

  Elice, F ^a   Rodeghiero, F ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

Author keywords

Antiangiogenic therapy; Bevacizumab; Bleeding

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; MONOCLONAL ANTIBODY;

ARTICLE; BLEEDING; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; HUMAN; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; HEMORRHAGE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 77955476115     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(10)70014-1     Document Type: Article

References (35)

1. Yang, JC, Haworth, L, Sherry, RM, et al. Randomized Trial of Bevacizumab, an Anti-Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer. N Engl J Med 349 (2003), 427–434.
2. Kabbinavar, F, Hurwitz, HI, Fehrenbacher, L, Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:1 (2003), 60–65.
3. Demetri, GD, van Oosterom, AT, Garrett, CR, Blackstein, ME, Shah, MH, Verweij, J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:9544 (2006), 1329–1338.
4. Motzer, RJ, Hutson, TE, Tomczak, P, Michaelson, MD, Bukowski, RM, Rixe, O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:2 (2007 Jan 11), 115–124.
5. Socinski, MA, Novello, S, Brahmer, JR, Rosell, R, Sanchez, JM, Belani, CP, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small cell lung cancer. J Clin Oncol 26:4 (2008), 650–656.
6. Miller, KD, Chap, LI, Holmes, FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23 (2005), 792–799.
7. Roche: Avastin Summary of Product Characteristics. 2005.
8. Hurwitz, H, Fehrenbacher, L, Novotny, W, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004), 2335–2342.
9. Kabbinavar, FF, Hambleton, J, Mass, RD, Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23 (2005), 3706–3712.
10. Giantonio, BJ, Levy, DE, O'Dwyer, PJ, Meropol, NJ, Catalano, PJ, Benson, AB 3rd, Eastern Cooperative Oncology Group. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. Ann Oncol 17:9 (2006 Sep), 1399–1403.
11. Giantonio, BJ, Catalano, PJ, Meropol, NJ, O'Dwyer, PJ, Mitchell, EP, Alberts, SR, et al., Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:12 (2007 Apr 20), 1539–1544.
12. Grothey, A, Sugrue, MM, Purdie, DM, Dong, W, Sargent, D, Hedrick, E, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 26:33 (2008 Nov 20), 5326–5334.
13. Allegra, CJ, Yothers, G, O'Connell, MJ, Sharif, S, Colangelo, LH, Lopa, SH, et al. Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 27:20 (2009), 3385–3390.
14. Shah, MA, Ramanathan, RK, Ilson, DH, Levnor, A, D'Adamo, D, O'Reilly, E, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 24:33 (2006 Nov 20), 5201–5206.
15. Sandler, A, Gray, R, Perry, MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 (2006), 2542–2550.
16. Cohen, MH, Gootenberg, J, Keegan, P, Pazdur, R, FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advancedmetastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12:6 (2007 Jun), 713–718.
17. Vredenburgh, JJ, Desjardins, A, Herndon, JE 2nd, Dowell, JM, Reardon, DA, Quinn, JA, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:4 (2007 Feb 15), 1253–1259.
18. Friedman, HS, Prados, MD, Wen, PY, Mikkelsen, T, Schiff, D, Abrey, LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:28 (2009 Oct 1), 4733–4740.
19. Escudier, B, Eisen, T, Stadler, WM, Szczylik, C, Oudard, S, Siebels, M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:2 (2007), 125–134.
20. Johnson, DH, Fehrenbacher, L, Novotny, WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22 (2004), 2184–2191.
21. Johnson, DH, Fehrenbacher, L, Novotny, WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22 (2004), 2184–2191.
22. Somer, RA, Sherman, E, Langer, CJ, Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599. Clin Lung Cancer 9:2 (2008), 102–105.
23. Sandler, AB, Schiller, JH, Gray, R, Dimery, I, Brahmer, J, Samant, M, et al. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab. J Clin Oncol 27:9 (2009), 1405–1412.
24. Rock, EP, Goodman, V, Jiang, JX, Mahjoob, K, Verbois, SL, Morse, D, et al. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 12:1 (2007 Jan), 107–113.
25. Escudier, B, Eisen, T, Stadler, WM, Szczylik, C, Oudard, S, Siebels, M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:2 (2007), 125–134.
26. Ratain, MJ, Eisen, T, Stadler, WM, Flaherty, KT, Kaye, SB, Rosner, GL, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16 (2006), 2505–2512.
27. Siu, LL, Awada, A, Takimoto, CH, Piccart, M, Schwartz, B, Giannaris, T, et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res 12:1 (2006 Jan 1), 144–151.
28. Kilickap S, Abali H, Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol;21(18):3542; author reply 3543.
29. Inai, T, Mancuso, M, Hashizume, H, Baffert, F, Haskell, A, Baluk, P, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 165:1 (2004), 35–52.
30. Kamba, T, Tam, BY, Hashizume, H, Haskell, A, Sennino, B, Mancuso, MR, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 290:2 (2006), H560–H576.
31. Dardik, R, Livnat, T, Seligsohn, U, Variable effects of alpha v suppression on VEGFR-2 expression in endothelial cells of different vascular beds. Thromb Haemost 102:5 (2009), 975–982.
32. Elice, F, Rodeghiero, F, Falanga, A, Rickles, FR, Thrombosis associated with angiogenesis inhibitors. Best Pract Res Clin Haematol 22:1 (2009), 115–128.
33. Elice, F, Jacoub, J, Rickles, FR, Falanga, A, Rodeghiero, F, Hemostatic complications of angiogenesis inhibitors in cancer patients. Am J Hematol 83:11 (2008), 862–870.
34. Hambleton, J, Skillings, J, Kabbinavar, F, Bergsland, E, Holmgren, E, Holden, SN, et al. Safety of low-dose aspirin (ASA) in a pooled analysis of 3 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol, 23(suppl), 2005, 259s (abstract 3554).
35. Hambleton, J, Novotny, WF, Hurwitz, H, Fehrenbacher, L, Cartwright, T, Hainsworth, J, et al. Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation. J Clin Oncol, 2(suppl), 2004 abstract 3528.